London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Evaluation of LamPORE rapid tests for Covid-19 show high levels of diagnostic sensitivityThe evaluation of the novel diagnostic platform for detecting SARS-CoV-2RNA was conducted by a team of scientists, including researchers from the University of SheffieldThe new technology has the potential to analyse thousands of samples per day on a single instrumentPreliminary results suggest high levels of diagnostic sensitivity in the new testing platform, which could mean an expansion to the scale of testing offered in the future to help control the pandemic.
A team of scientists, including researchers from the University of Sheffield, have today (25 September 2020) published their evaluation of a rapid, new Covid-19 testing technology, which has the potential to expand the type and scale of testing available.
LamPORE, a novel diagnostic platform for detecting SARS-CoV-2RNA, combines loop-mediated isothermal amplification with nanopore sequencing, meaning it has the potential to analyse thousands of samples per day on a single instrument.
Although preliminary, the results suggest high levels of diagnostic sensitivity in LamPORE which could mean an expansion to the scale of testing that could be offered in the future to help control the SARS-CoV-2 pandemic.
The collaboration between the University of Sheffield and colleagues at Public Health England Porton Down (PHE), Sheffield Teaching Hospitals NHS Foundation Trust and the University of Oxford, including support from the NIHR Oxford Biomedical Research Centre, evaluated the performance of LamPORE against RT-PCR - the most commonly-used laboratory test for Covid-19.
These are preliminary but promising data that suggest LamPORE has the potential to expand the type and scale of SARS-CoV-2 testing that could be offered in the future.
DR THUSHAN DE SILVA, UNIVERSITY OF SHEFFIELD
The team used RNA (Ribonucleic acid which is a polymeric molecule essential in various biological roles in coding, decoding, regulation and expression of genes) extracted from two types of samples. Initially, mock samples formed of saliva from people without infection that had a known quantity of virus added to it, and subsequently nose and throat swabs from real Covid-19 patients collected during routine care at two UK hospitals - Oxford University Hospitals NHS Foundation Trust and Sheffield Teaching Hospitals NHS Foundation Trust.
The positive clinical specimens came mostly from patients with symptomatic infection, and among these LamPORE had a diagnostic sensitivity of 99.1 per cent (i.e. it was positive in 226 of 228 samples positive by RT-PCR).
Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6 per cent (i.e. it was negative in 278 of 279 samples negative by RT-PCR). Overall, 1.4 per cent of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducib
"There are a number of technologies that are coming through that are really fast".
Key here is whether our test works regardless of whether they are speaking about us or not. If it does and if it fast and accurate then yes our test will be rolled out everywhere. Therefore a market cap of at least a few hundred million would be fair as a starting point.
Could that article be referring to our test or would we have been told by now if Porton Down where involved? Paraytec certainly fits the bill. Guess we we will find out Monday.
From 5th August paraytec update: "Our approach, in which viral attachment to affinity macromolecules may be imaged directly using a highly sensitive detection system, has the potential both to undertake many tests in parallel, as well as delivering results in minutes, all without the need for trained health professionals for their operation."
Yep lot better than this vaccine passport who knows with all variants only way out is test test companys need to pay for tests for employees well paying enough in tax this will be spot on test hopefully and for shareholders and to get out this mess
Scientists at the chemical weapons testing laboratory at Porton Down are working on rapid Covid tests that can diagnose tens of thousands of people an hour to unlock the British summer of sport.
Porton Down scientists are verifying a number of different schemes for mass testing for thousands of spectators in a matter of minutes in order to allow for sports events in June.
The tests could see tens of thousands of fans checked an hour before going to watch events at stadia this summer, according to industry sources familiar with the plan.
One testing source told The Telegraph: "There are possibilities that involve being able to process tens of thousands of tests an hour.
"Technology has been adapted from agriculture and other areas where high volume processing is the norm and is being applied to this human application like never before."
Health ministers commissioned PHE Porton Down to establish a time-limited SARS-CoV-2 test development and evaluation programme last August.
Since then, a scientific team has been established to deliver this work in collaboration with the University of Oxford and Porton Down's external scientific advisers through a three-stage process.
By the end of the testing process, thousands of the tests are being checked by the scientists at Porton Down. The findings are then reported to officials and ministers who use "this information and any recommendations to inform potential purchasing decisions".
One senior Government source said: "There are a number of technologies that are coming through that are really very fast. [Porton Down] is looking at the efficacy and the accuracy. There are a number of them under testing at the moment. It is very very fast – volume and speed."
Last week Nadhim Zahawi, the vaccines minister, made it clear in an online forum with the Reaction website that mass rapid testing will be a large part of how the UK returns to normal after the pandemic.
Mr Zahawi said: "We think that rapid testing is one of the ways that we open the economy, whether it be large concerts or other parts of the economy. So testing certification needs to be easily available on your phone if you need to show you have had a test if you need to attend a sporting event or anything else."
A Department of Health and Social Care spokesman declined to comment.
A source pointed to the Government's plan for exiting the lockdown, which said pilot testing for "enhanced testing approaches and other measures to run events with larger crowd sizes and reduced social distancing to evaluate the outcomes" starts in April.
The plan added: "The Government will bring the findings from across different sectors and different settings to determine a consistent approach to lifting restrictions on these events."